Chronic kidney disease (ckd)
Drug research and approvals for chronic kidney disease (ckd): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 434 studies of chronic kidney disease (ckd) are recruiting on ClinicalTrials.gov, Health Canada has authorized 45 drug trials for it since 2013, FDA has 1 approved and 2 open orphan designations naming it, and the EU has 10 authorised medicines for it.
- Recruiting worldwide: 434
- Trials authorized in Canada: 45
- FDA orphan approvals: 1
- EU medicines: 10
Recruiting Now
Newest start dates first, of 434 recruiting on ClinicalTrials.gov ↗- Breakthrough - T1DM and Chronic Kidney DiseaseNCT07592000 · Phase 1 / Phase 2 · University of Chicago · starts Apr 29, 2027
- Effects of Replacing High Protein Foods in People With Chronic Kidney DiseaseNCT07105670 · Not applicable · Indiana University · starts Feb 1, 2027
- Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine,…NCT07083557 · Not reported · Bettina Mittendorfer · starts Jan 1, 2027
- Intradialytic Benson's Relaxation Technique in Patients With Chronic Kidney DiseaseNCT07935980 · Not applicable · Cairo University · starts Dec 1, 2026
- Clinical Decision Support for SGLT2i After AKI in Type 2 DiabetesNCT07868666 · Not applicable · University of Minnesota · starts Nov 2, 2026
- Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney DiseaseNCT07911124 · Phase 2 · University of Arkansas · starts Nov 1, 2026
- Bone Deterioration After Kidney Transplantation Assessed by DXA and HR-pQCTNCT07935915 · Not reported · Medical University Innsbruck · starts Oct 21, 2026
- A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated…NCT07900438 · Phase 4 · Novo Nordisk A/S · starts Oct 12, 2026
- Effect of Synbiotic Therapy on Renal Function Outcomes in Patients With Chronic Kidney Disease Stage III-IV: A…NCT07912359 · Not applicable · Chittagong Medical College · starts Oct 11, 2026
- Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and HyperuricaemiaNCT07323095 · Phase 2 · Atom Therapeutics Co., Ltd · starts Oct 2, 2026
Trials Authorized in Canada
The 10 newest of 45; search them all in Canada trials| Nov 13, 2026 | A phase 1, randomized, double-blinded, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and…EPRA-0322 | EPOK THERAPEUTICS INC. | Pending |
| Jul 30, 2026 | A phase III, randomised, double-blind, study to evaluate the effect of balcinrenone/dapagliflozin compared with dapagliflozin on renal and cardiovascular…BALCINRENONE-DAPAGLIFLOZIN (AZD2961) / DAPAGLIFLOZIN | AstraZeneca Pharmaceuticals LP | Ongoing |
| May 12, 2026 | A phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the effect of elecoglipron in reducing renal outcomes…ELECOGLIPRON (AZD5004) / DAPAGLIFLOZIN | AstraZeneca Pharmaceuticals LP | Ongoing |
| Nov 12, 2025 | A phase IIb, randomised, multicentre, double-blind study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat on…BAXDROSTAT / DAPAGLIFLOZIN | AstraZeneca Pharmaceuticals LP | Ongoing |
| Sep 22, 2025 | A phase 3, randomized, double-blind, placebo-controlled, event-driven study to investigate the effect of orforglipron on the incidence of major adverse…ORFORGLIPRON (LY3502970) | Eli Lilly | Ongoing |
| Jul 30, 2025 | A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the pharmacokinetics, safety, and efficacy of empagliflozin tablets…EMPAGLIFLOZIN | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Ongoing |
| Oct 15, 2024 | A phase III, randomised, double-blind, placebo-controlled, event-driven study to assess the efficacy, safety and tolerability of baxdrostat in combination with…BAXDROSTAT / DAPAGLIFLOZIN | AstraZeneca Pharmaceuticals LP | Ongoing |
| Jun 6, 2024 | Studies of heart & kidney protection with bi 690517 in combination with empagliflozin: a multicenter, international, randomized, double-blind,…VICADROSTAT (BI 690517) / EMPAGLIFLOZIN | Boehringer Ingelheim Pharmaceuticals, Inc. | Ongoing |
| Apr 8, 2024 | An 18-month, open-label, single-arm safety extension study of an age- and bodyweight-adjusted oral finerenone regimen, in addition to an acei or arb, for the…FINERENONE (BAY-94-8862) | Bayer | Ongoing |
| Apr 4, 2024 | A phase 3, randomized, double-blind, placebo-controlled, event-driven study to investigate the effect of retatrutide on the incidence of major adverse…RETATRUTIDE (LY3437943) | Eli Lilly | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Oct 18, 2016 | ZemplarIndicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism… | Abbvie, inc. | Approved |
| Sep 7, 2016 | cinacalcetTreatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease receiving dialysis | Amgen, Inc. | Designated |
| Apr 3, 2009 | vonapanitasePrevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving… | Proteon Therapeutics, Inc. | Designated |
Medicines Authorised in the EU
Newest first| May 29, 2026 | Bopediatfurosemide | Proveca Pharma Limited | EMA ↗ |
| Jun 11, 2025 | Xoanacylferric citrate coordination complex | Averoa | EMA ↗ |
| Apr 24, 2023 | Vafseovadadustat | Medice Arzneimittel Pütter GmbH & Co. KG | EMA ↗ |
| Apr 25, 2022 | Kapruviadifelikefalin | Vifor Fresenius Medical Care Renal Pharma France | EMA ↗ |
| Feb 16, 2022 | Kerendiafinerenone | Bayer AG | EMA ↗ |
| Aug 18, 2021 | Evrenzoroxadustat | Astellas Pharma Europe B.V. | EMA ↗ |
| Nov 11, 2016 | Parsabivetelcalcetide | Amgen Europe B.V. | EMA ↗ |
| May 27, 2015 | Jinarctolvaptan | Otsuka Pharmaceutical Netherlands B.V. | EMA ↗ |
| Aug 26, 2014 | Velphorosucroferric oxyhydroxide | Vifor Fresenius Medical Care Renal Pharma France | EMA ↗ |
| Jul 20, 2007 | Mirceramethoxy polyethylene glycol-epoetin beta | Roche Registration GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA